Research Report University Hospital for clinical assessment TPU-S1119

Abstract

A phase 1, open-label, non-randomized, dose-finding, safety and tolerability study of orally administered Teysuno (S1) in combination with Epirubicin and Oxaliplatin in patients with advanced solid tumors

Keywords

• advanced solid tumors
• Teysuno (S1)
• epirubicin
• oxaliplatin